NASDAQ · BHST
Basic Materials · Agricultural Inputs
$1.46
Down-$0.08 (-5.19%)
Updated Nov 5, 2026, 1:24 PM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BHST
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
BHST closed at $1.46 after 21 trading sessions, down 2.01% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $1.53 | $1.53 | $1.46 | $1.46 | 9.61K |
| Nov 3, 2026 | $1.58 | $1.60 | $1.52 | $1.54 | 8.16K |
| Nov 2, 2026 | $1.63 | $1.65 | $1.56 | $1.57 | 20.81K |
| Oct 30, 2026 | $1.665 | $1.67 | $1.64 | $1.66 | 2.54K |
| Oct 29, 2026 | $1.75 | $1.76 | $1.65 | $1.66 | 20.43K |
| Oct 28, 2026 | $1.69 | $1.78 | $1.68 | $1.76 | 30.77K |
| Oct 27, 2026 | $1.6799 | $1.70 | $1.6409 | $1.70 | 12.9K |
| Oct 26, 2026 | $1.70 | $1.80 | $1.625 | $1.68 | 16.42K |
| Oct 23, 2026 | $1.8299 | $1.8299 | $1.6501 | $1.72 | 25.35K |
| Oct 22, 2026 | $1.6699 | $1.78 | $1.63 | $1.68 | 13.26K |
| Oct 21, 2026 | $1.675 | $1.695 | $1.61 | $1.672 | 7.32K |
| Oct 20, 2026 | $1.735 | $1.74 | $1.6501 | $1.68 | 11.3K |
| Oct 19, 2026 | $1.85 | $1.85 | $1.7683 | $1.80 | 19.32K |
| Oct 16, 2026 | $1.53 | $1.85 | $1.53 | $1.85 | 6.57K |
| Oct 15, 2026 | $1.77 | $1.79 | $1.5301 | $1.70 | 16.04K |
| Oct 14, 2026 | $1.84 | $1.84 | $1.5214 | $1.745 | 19.56K |
| Oct 13, 2026 | $1.65 | $1.84 | $1.65 | $1.82 | 33.29K |
| Oct 12, 2026 | $1.66 | $1.66 | $1.62 | $1.62 | 9.78K |
| Oct 9, 2026 | $1.5054 | $1.69 | $1.45 | $1.66 | 17.15K |
| Oct 8, 2026 | $1.494 | $1.5461 | $1.49 | $1.495 | 17.19K |
| Oct 7, 2026 | $1.46 | $1.49 | $1.371 | $1.49 | 15.72K |
The latest Smart Investors Daily articles mentioning BHST.
Company
Market Activity
Research & News
BHST research
Company profile and research snapshot.
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Oct 13, 2026
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Tuesday that Olive Cell, an olive-derived plant-cell ingredient, is ready for commercial licensing, the second product from its Botanical Synthesis technology to reach that stage. The company said Olive Cell has completed large-scale...
Yahoo · Oct 13, 2026
Botanical Synthesis™-developed asset has now completed development, commercial-scale manufacturing and the applicable self-affirmed GRAS process and is ready for production at BioHarvest's GMP facilityMilestone demonstrates BioHarvest's ability to create proprietary plant-derived assets and advance them from plant-cell development through industrial manufacturing and commercializationHigh-potency proprietary olive-derived Verbascoside composition demonstrates promising dose-dependent preclinical
Benzinga · Oct 13, 2026
Botanical Synthesis™-developed asset has now completed development, commercial-scale manufacturing and the applicable self-affirmed GRAS process and is ready for production at BioHarvest's GMP facilityMilestone
Yahoo · Oct 8, 2026
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Thursday its Botanical Synthesis platform can produce the next-generation sweetener targeted in its joint development program with Tate & Lyle. Tate & Lyle, a supplier of ingredient solutions for food and beverages, is looking...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BHST.
